UY27776A1 - Compuestos de 3,4-dihidroquinolin-2( 1h ) -ona como antagonistas del receptor nr2b - Google Patents
Compuestos de 3,4-dihidroquinolin-2( 1h ) -ona como antagonistas del receptor nr2bInfo
- Publication number
- UY27776A1 UY27776A1 UY27776A UY27776A UY27776A1 UY 27776 A1 UY27776 A1 UY 27776A1 UY 27776 A UY27776 A UY 27776A UY 27776 A UY27776 A UY 27776A UY 27776 A1 UY27776 A1 UY 27776A1
- Authority
- UY
- Uruguay
- Prior art keywords
- compound
- dihydroquinolin
- disease
- receptor antagonists
- pharmaceutically acceptable
- Prior art date
Links
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 2
- 230000009529 traumatic brain injury Effects 0.000 abstract 2
- ZTOSZJPNPROTBL-FQEVSTJZSA-N 6-[(1r)-2-[4-(3-fluorophenyl)-4-hydroxypiperidin-1-yl]-1-hydroxyethyl]-3,4-dihydro-1h-quinolin-2-one Chemical group C([C@H](O)C=1C=C2CCC(=O)NC2=CC=1)N(CC1)CCC1(O)C1=CC=CC(F)=C1 ZTOSZJPNPROTBL-FQEVSTJZSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 abstract 1
- 102000034527 Retinoid X Receptors Human genes 0.000 abstract 1
- 108010038912 Retinoid X Receptors Proteins 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37593902P | 2002-04-26 | 2002-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY27776A1 true UY27776A1 (es) | 2003-11-28 |
Family
ID=29270728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY27776A UY27776A1 (es) | 2002-04-26 | 2003-04-24 | Compuestos de 3,4-dihidroquinolin-2( 1h ) -ona como antagonistas del receptor nr2b |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6713490B2 (enExample) |
| EP (1) | EP1499606B8 (enExample) |
| JP (1) | JP2005524696A (enExample) |
| AR (1) | AR039663A1 (enExample) |
| AT (1) | ATE325117T1 (enExample) |
| AU (1) | AU2003219398A1 (enExample) |
| BR (1) | BR0309778A (enExample) |
| CA (1) | CA2483636A1 (enExample) |
| DE (1) | DE60305026T2 (enExample) |
| ES (1) | ES2258716T3 (enExample) |
| MX (1) | MXPA04010549A (enExample) |
| PA (1) | PA8572601A1 (enExample) |
| TW (1) | TW200406402A (enExample) |
| UY (1) | UY27776A1 (enExample) |
| WO (1) | WO2003091241A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3693258B2 (ja) | 1996-07-24 | 2005-09-07 | ワーナー―ランバート・コンパニー | イソブチルｇａｂａまたはその誘導体を含有する鎮静剤 |
| BRPI0415113A (pt) * | 2003-10-08 | 2006-11-28 | Pfizer | compostos de lactama condensados |
| ES2246687B2 (es) * | 2004-02-11 | 2006-11-16 | Miguel Muñoz Saez | Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales. |
| JPWO2005097782A1 (ja) * | 2004-04-07 | 2007-08-16 | 協和醗酵工業株式会社 | ピペリジン誘導体 |
| HU226977B1 (en) * | 2004-07-29 | 2010-04-28 | Richter Gedeon Nyrt | Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them |
| US9744137B2 (en) * | 2006-08-31 | 2017-08-29 | Supernus Pharmaceuticals, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
| US8008253B2 (en) * | 2007-07-03 | 2011-08-30 | Andrew Tasker | Treatment for anxiety |
| SG176464A1 (en) | 2008-05-09 | 2011-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| AU2009296457A1 (en) | 2008-09-27 | 2010-04-01 | Taraxos Inc. | Topical formulations for treatment of neuropathy |
| US20120077883A1 (en) * | 2009-03-31 | 2012-03-29 | De Barros Coelho Claudia Couto | Treatment of tinnitus and associated auditory dysfunctions |
| WO2011145062A1 (en) | 2010-05-21 | 2011-11-24 | Link Research & Grants Corporation | Treatment of tinnitus and related auditory dysfunctions |
| WO2012042314A1 (en) | 2010-10-02 | 2012-04-05 | Link Research & Grants Corporation | Treatment of tinnitus and related auditory dysfunctions |
| US9387212B2 (en) | 2012-04-20 | 2016-07-12 | Ucb Biopharma Sprl | Methods for treating Parkinson's disease |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4902695A (en) | 1989-02-13 | 1990-02-20 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| RU2068414C1 (ru) | 1990-05-10 | 1996-10-27 | Пфайзер Инк. | Производные индолона в виде рацемата или оптически активного изомера или их фармацевтически приемлемые аддитивные соли кислоты и кетопроизводные индолона |
| NZ255074A (en) | 1992-10-30 | 1996-10-28 | Pfizer | 6-[2-(4-hydroxy-4-(4-substituted phenyl)piperidino)-1-hydroxypropyl]-3,4-dihydro-2(1h)-quinolones |
| US6407235B1 (en) | 2000-08-21 | 2002-06-18 | Hoffmann-La Roche Inc. | Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol |
-
2003
- 2003-04-14 US US10/413,029 patent/US6713490B2/en not_active Expired - Fee Related
- 2003-04-15 WO PCT/IB2003/001556 patent/WO2003091241A1/en not_active Ceased
- 2003-04-15 EP EP03715209A patent/EP1499606B8/en not_active Expired - Lifetime
- 2003-04-15 AU AU2003219398A patent/AU2003219398A1/en not_active Abandoned
- 2003-04-15 JP JP2003587800A patent/JP2005524696A/ja not_active Withdrawn
- 2003-04-15 MX MXPA04010549A patent/MXPA04010549A/es not_active Application Discontinuation
- 2003-04-15 ES ES03715209T patent/ES2258716T3/es not_active Expired - Lifetime
- 2003-04-15 DE DE60305026T patent/DE60305026T2/de not_active Expired - Fee Related
- 2003-04-15 BR BR0309778-1A patent/BR0309778A/pt not_active IP Right Cessation
- 2003-04-15 AT AT03715209T patent/ATE325117T1/de not_active IP Right Cessation
- 2003-04-15 CA CA002483636A patent/CA2483636A1/en not_active Abandoned
- 2003-04-24 UY UY27776A patent/UY27776A1/es not_active Application Discontinuation
- 2003-04-24 AR ARP030101424A patent/AR039663A1/es unknown
- 2003-04-25 TW TW092109786A patent/TW200406402A/zh unknown
- 2003-04-25 PA PA20038572601A patent/PA8572601A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003219398A1 (en) | 2003-11-10 |
| ATE325117T1 (de) | 2006-06-15 |
| BR0309778A (pt) | 2005-03-08 |
| EP1499606B8 (en) | 2006-08-30 |
| EP1499606A1 (en) | 2005-01-26 |
| EP1499606B1 (en) | 2006-05-03 |
| US6713490B2 (en) | 2004-03-30 |
| ES2258716T3 (es) | 2006-09-01 |
| WO2003091241A1 (en) | 2003-11-06 |
| DE60305026D1 (de) | 2006-06-08 |
| CA2483636A1 (en) | 2003-11-06 |
| TW200406402A (en) | 2004-05-01 |
| DE60305026T2 (de) | 2006-10-12 |
| PA8572601A1 (es) | 2004-12-16 |
| MXPA04010549A (es) | 2005-02-17 |
| AR039663A1 (es) | 2005-03-02 |
| US20030216430A1 (en) | 2003-11-20 |
| JP2005524696A (ja) | 2005-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY27776A1 (es) | Compuestos de 3,4-dihidroquinolin-2( 1h ) -ona como antagonistas del receptor nr2b | |
| CL2011001263A1 (es) | Compuestos derivados de pirimidinonas opcionalmente sustituidas; composicion farmaceutica que los comprende; y su uso como inhibidores de fosfodiesterasa 1 (pde1) para el tratamiento de enfermedades que involucran trastornos de la trayectoria intracelular del receptor de dopamina d1 como parkinson, alzheimer, depresion, enfermedad bipolar, hipertension, glaucoma. | |
| RU2015112914A (ru) | Бензимидазолы в качестве активных агентов для центральной нервной системы | |
| IL178747A (en) | 3 - (4-amino-1-oxo-1, 3-dihydro-isoindole-2-yl) -pipridine-6,2-discussion or acceptable pharmaceutical salt, solvate or steroid isomer for use in the treatment of non-Hodgkin's lymphoma, also optional Combined with other therapeutic factors | |
| DOP2013000263A (es) | Compuestos de 2- (2,4,5-anilino sustituido) pirimidina derivados como moduladores de egfr utilizados para el tratamiento del cáncer | |
| MA30798B1 (fr) | Thiazole pyrazolopyrimidines comme antigonistes du recepteur crf1 | |
| TN2018000130A1 (en) | N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases | |
| PE20240646A1 (es) | Compuestos farmaceuticos | |
| JP2005539012A5 (enExample) | ||
| JP2005510473A5 (enExample) | ||
| FI3406609T3 (fi) | Bisyklisiä atsayhdisteitä muskariinireseptorin agonisteina | |
| US20170096426A1 (en) | Novel Tricyclic Modulators of Cannabinoid Receptors | |
| BRPI0408988A (pt) | composto de piperidinilamino-tieno[2,3-d]pirimidina | |
| BR0215801A (pt) | Derivados de 3,6-dissubstituìdos azabiciclo [3.1.0] hexano úteis como antagonistas de receptores muscarìnicos | |
| CL2007002899A1 (es) | Compuestos derivados de azaciclilaminas n-sustituidas, inhibidores del receptor de histamina 3; proceso de preparacion; composicion farmaceutica que comprende los compuestos, y usopara el tratamiento de trastornos cognitivos, esquizofre nia y enfermedad de alzheimer entre otros. | |
| ATE409480T1 (de) | Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren | |
| JOP20210020A1 (ar) | معدلات عطرية غير متجانسة لمستقبل nmda واستخداماتها | |
| DE602004015603D1 (de) | Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren | |
| ECSP056192A (es) | 3-fluoro-piperidinas como antagonistas de nmda/nr2b | |
| CL2009000491A1 (es) | Compuestos derivados de 3-(4-(2-oxoindol)-piperidin)-pirrolidinas y 3-(4-benzo[b]imidazol)-piperidin)-pirrolidinas sustituidas proceso de preparacion; composicion farmaceutica; compuestos intermediarios; utiles en el tratamiento de la terapia del dolor, de enfermedades tales como alzheimer, ansiedad, depresion y glaucoma. | |
| NO20090190L (no) | Modulatorer av kjemokin reseptor aktivitet, krystallinske former og fremgangsmate | |
| EP4431157A3 (en) | 1-[[(3s)-3-methyl-6-(4(4,4-trifluorobutoxy)-3,4-dihydronaphthalen-2yl]methyl]azetidine-3-carboxylic acid having s1p5 receptor agonist activity for the treatment of neurodegenerative disorders and cancer | |
| WO2004030629A3 (en) | Novel neurokinin antagonists and methods of use thereof | |
| JP2005524696A5 (enExample) | ||
| CO6660425A2 (es) | Compuestos para el tratamiento de trastornos neurológicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 104 | Application deemed to be withdrawn (no substantive examination fee paid) |
Effective date: 20101123 |